[Low-grade non-Hodgkin lymphoma in Northern Norway]. 2002

Anders Vik, and Nina Helbekkmo, and Roy M Bremnes
Medisinsk avdeling, Regionsykehuset i Tromsø 9038 Tromsø. anders.vik@rito.no

BACKGROUND We present a study of treatment outcome and evaluate pre-treatment prognostic factors in patients treated for low-grade non-Hodgkin's lymphoma (LG-NHL) at our institution during a ten-year period. METHODS 169 consecutively registered patients from 1986 to 1996 were retrospectively analysed with regard to demographic, treatment, and disease-specific characteristics. Median follow-up time was 52 months. All patients were diagnosed histologically according to the previous Kiel classification system. Median age was 60 years; the male:female ratio was 1.05:1. RESULTS The response rate was 66%; median overall survival 8.3 years. Five and ten-year overall survival were 72% and 47% respectively. For stage 1, 2, 3 and 4, ten-year overall survival were 86%, 65%, 33% and 29%. Of the pre-treatment parameters, advanced stage, B-symptoms, poor performance status, bone marrow infiltration, tumour > or = 6 cm, low serum albumin, anaemia, and LD > or = 540 U/l were all related to survival. According to the multivariate analysis, stage, performance status, tumour size, and anaemia were found to be independent prognostic factors for overall survival. CONCLUSIONS The strategy of radiation therapy has proved successful for most patients with stage 1 disease. Independent prognostic factors for overall survival such as stage, performance status, tumour size, and anaemia may be useful guides in deciding when and how to treat.

UI MeSH Term Description Entries
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009664 Norway A country located in northern Europe, bordering the North Sea and the Atlantic Ocean, west of Sweden. The capital is Oslo. Kingdom of Norway
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Anders Vik, and Nina Helbekkmo, and Roy M Bremnes
October 1988, European journal of haematology,
Anders Vik, and Nina Helbekkmo, and Roy M Bremnes
January 1989, American journal of hematology,
Anders Vik, and Nina Helbekkmo, and Roy M Bremnes
March 2003, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Anders Vik, and Nina Helbekkmo, and Roy M Bremnes
April 2008, The Journal of steroid biochemistry and molecular biology,
Anders Vik, and Nina Helbekkmo, and Roy M Bremnes
August 1996, Nederlands tijdschrift voor geneeskunde,
Anders Vik, and Nina Helbekkmo, and Roy M Bremnes
October 2000, Nederlands tijdschrift voor geneeskunde,
Anders Vik, and Nina Helbekkmo, and Roy M Bremnes
July 2007, Seminars in radiation oncology,
Anders Vik, and Nina Helbekkmo, and Roy M Bremnes
January 1999, Acta oncologica (Stockholm, Sweden),
Anders Vik, and Nina Helbekkmo, and Roy M Bremnes
January 1996, European neurology,
Anders Vik, and Nina Helbekkmo, and Roy M Bremnes
September 2002, Archives of ophthalmology (Chicago, Ill. : 1960),
Copied contents to your clipboard!